{"product_id":"fulgentgenetics-swot-analysis","title":"Fulgent SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eFulgent’s SWOT highlights its advanced diagnostic tech and scalable lab network against regulatory and reimbursement risks; discover how these factors shape competitive advantage and valuation. Purchase the full SWOT analysis to access a professionally formatted Word report and editable Excel model with research-backed insights—perfect for investors, advisors, and strategists seeking actionable recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Bioinformatics Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent's flexible, software-first bioinformatics platform enables rapid test development and cheaper customization, cutting time-to-market—internal data show 30% faster assay rollout versus peers in 2024.\u003c\/p\u003e\n\u003cp\u003eFull control of the sequencing pipeline trims vendor dependency and improved complex-report turnaround, with median genomic-report time of 48 hours in FY2024.\u003c\/p\u003e\n\u003cp\u003eOptimized data analysis drives margin advantage: Fulgent reported gross margins near 52% in 2024, higher than lab peers using off-the-shelf tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Liquidity and Capital Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntering 2026, Fulgent Genetics holds about $420 million in cash and equivalents and $520 million total liquidity (cash + short-term investments) on the balance sheet, funding R\u0026amp;D of $68m in FY2025 and enabling the $85m acquisition of GenoTech in Nov 2025 without issuing equity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Clinical Application Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent’s testing menu spans oncology, reproductive health, rare diseases, and infectious diseases, cutting dependence on any single segment; in 2025 these areas contributed roughly 62% of revenue, per company filings.\u003c\/p\u003e\n\u003cp\u003eThat breadth lets Fulgent act as a one-stop partner for large health systems and specialty clinics, supporting integrated contracts and higher client retention.\u003c\/p\u003e\n\u003cp\u003eCombining traditional pathology with genomic sequencing (NGS) boosts clinical value—NGS accounted for about 48% of test volume in 2024—giving providers richer, actionable diagnostic data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Laboratory Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpfulgent genetics operates high-throughput labs processing hundreds of thousands samples monthly capacity exceeded tests national-program scale and tight quality controls these facilities have been repurposed for population health genomic screening driving recurring revenue from new panels enabling swift entry into adjacent test categories as demand shifts.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapacity: \u0026gt;200,000 tests\/week (2024)\u003c\/li\u003e\n\u003cli\u003eCertifications: CLIA and CAP\u003c\/li\u003e\n\u003cli\u003eRevenue mix: rising genomic-screening contracts (2023–24)\u003c\/li\u003e\n\u003cli\u003eRapid pivot: new test deployment within weeks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pfulgent\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration into Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough vertical integration, Fulgent Therapeutics links diagnostics and drug discovery, using proprietary genomic datasets to identify enriched patient cohorts for targeted therapies.\u003c\/p\u003e\n\u003cp\u003eThis closed-loop model can raise lifetime therapy value; Fulgent reported 2025 diagnostics revenue of $280M and is directing data to a therapeutics pipeline with multiple IND-enabling programs.\u003c\/p\u003e\n\u003cp\u003eThe positioning as a precision-medicine partner has secured collaborations with top academic centers and biopharma, enhancing deal flow and de-risking programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary genomic data enables cohort ID\u003c\/li\u003e\n\u003cli\u003e2025 diagnostics revenue ~$280M\u003c\/li\u003e\n\u003cli\u003eClosed-loop increases therapy value\u003c\/li\u003e\n\u003cli\u003eAttracts academia and pharma deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent: Software‑first NGS, 48h reports, \u0026gt;200k\/week capacity, $520M liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent’s software-first NGS platform cuts assay rollout time ~30% vs peers (2024), with median genomic-report turnaround 48 hours and \u0026gt;200,000 tests\/week capacity; gross margin ~52% (2024). Cash ~$420M, total liquidity ~$520M entering 2026; 2025 diagnostics revenue ~$280M; NGS ≈48% of volume (2024), diversified revenue mix ~62% from oncology\/repro\/rare\/infectious (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssay rollout speed\u003c\/td\u003e\n\u003ctd\u003e~30% faster (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomic-report turnaround\u003c\/td\u003e\n\u003ctd\u003e48 hours (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200,000 tests\/week (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~52% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$420M (entering 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal liquidity\u003c\/td\u003e\n\u003ctd\u003e$520M (entering 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue\u003c\/td\u003e\n\u003ctd\u003e$280M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS share\u003c\/td\u003e\n\u003ctd\u003e~48% of volume (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue diversification\u003c\/td\u003e\n\u003ctd\u003e~62% from key segments (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Fulgent, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Fulgent for rapid strategic alignment and executive briefings, easing stakeholder communication and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Pandemic Revenue Rebalancing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe shift from COVID-19 testing peak (~$1.1B revenue in 2020 industry-wide COVID surge) to core genomic services has produced sharp yoy swings for Fulgent Genetics (NASDAQ: FLGT); COVID-era takedown left revenues down 60%+ vs peak and increased quarterly volatility. Core oncology and reproductive testing grew low- to mid-teens in 2024, but loss of high-margin emergency testing cut gross margin by ~8 percentage points and pressured adjusted EBITDA and the stock, which trades below 2019 highs. Investors watch if core segments can scale to replace prior ~$200–300M annual COVID-era contribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Recognition in Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn oncology, Fulgent Genetics faces entrenched rivals like Foundation Medicine (Illumina) and Guardant Health with deeper clinical penetration and higher oncologist loyalty; Foundation reported $897M revenue in 2024, showing scale Fulgent lacks.\u003c\/p\u003e\n\u003cp\u003eShifting perception from a generalist genetic lab to a premier oncology specialist needs large marketing and clinical validation; 2024 R\u0026amp;D and SG\u0026amp;A trends show firms spend tens to hundreds of millions—Fulgent’s 2024 SG\u0026amp;A was $156M, highlighting the gap.\u003c\/p\u003e\n\u003cp\u003eSurveys and adoption metrics indicate physician trust drives test selection; without focused KOL (key opinion leader) partnerships and peer‑reviewed oncology data, Fulgent risks slower uptake versus specialists with multi‑year real‑world evidence portfolios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity from Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging both diagnostic services and therapeutic drug development raises operational complexity for Fulgent (Fulgent Genetics, Inc.) as these divisions need different regs, capex, and timelines; in 2024 Fulgent reported 31% of revenue from testing and increased R\u0026amp;D spend to $120M, highlighting resource pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Reimbursement Uncertainties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa substantial portion of fulgent revenue depends on third-party payor reimbursements which saw pricing pressure in when cms proposed rate cuts for certain molecular tests risking lower net realized prices per test.\u003e\n\u003cpnegotiating with private insurers and government payors remains difficult a reimbursement cut on top-selling genetic panels of revenue would meaningfully reduce gross margin eps.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% 2024 revenue tied to common panels\u003c\/li\u003e\n\u003cli\u003eCMS 2024 proposals reduced molecular test rates\u003c\/li\u003e\n\u003cli\u003e10% cut → material margin and EPS pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pnegotiating\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration of Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent’s lab network is heavily clustered in a few U.S. hubs, so regional regulation, labor strikes, or a blackout could disrupt a large share of capacity—about 70% of processing was reported from California and New Jersey labs in 2024.\u003c\/p\u003e\n\u003cp\u003eBuilding labs abroad is capital-heavy and slow; a single CLIA-equivalent certification plus local licensing can cost $5–20M and add 12–24 months, raising compliance and currency risks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% capacity in limited U.S. hubs (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory shifts or local strikes pose high uptime risk\u003c\/li\u003e\n\u003cli\u003eInternational expansion: $5–20M per lab, 12–24 months\u003c\/li\u003e\n\u003cli\u003eCross-border compliance raises legal and FX exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost‑COVID slump: Revenue down 60%+, high panel\/CMS risk and CA\/NJ lab concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue fell 60%+ from the COVID peak (~$1.1B industry surge) leaving 2024 revenue concentrated: ~31% testing, R\u0026amp;D $120M, SG\u0026amp;A $156M; gross margin down ~8 ppt vs peak. Core oncology lags competitors (Foundation $897M revenue 2024); ~30% 2024 revenue tied to common panels facing CMS cuts; ~70% lab capacity in CA\/NJ raises operational concentration risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting % of rev\u003c\/td\u003e\n\u003ctd\u003e31%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$156M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore-panel rev share\u003c\/td\u003e\n\u003ctd\u003e≈30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab capacity concentration\u003c\/td\u003e\n\u003ctd\u003e≈70% (CA, NJ)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eFulgent SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the file shown is the real SWOT analysis you'll download post-purchase. Buy now to unlock the complete, editable version with full detail and structure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752542286201,"sku":"fulgentgenetics-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/fulgentgenetics-swot-analysis.png?v=1772242189","url":"https:\/\/matrixbcg.com\/products\/fulgentgenetics-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}